EPISODE · Aug 20, 2025 · 43 MIN
Episode 64. Lymphoma Updates from EHA and ICML 2025 with Dr. Adrian Minson
from Blood Cancer Talks · host Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific antibodies in various combinations and treatment settings for diffuse large B-cell lymphoma (DLBCL).Key Clinical Trials Discussed1. POLARGO Trial - Polatuzumab + R-GemOx vs R-GemOx in R/R DLBCL2. SUNMO Trial - Mosunetuzumab + Polatuzumab vs R-GemOx in R/R DLBCL3. STARGLO Trial - Glofitamab + GemOx vs R-GemOx in R/R DLBCL (2-Year Update)4. EPCORE NHL-5 & NHL-7 - Epcoritamab Combinations in Frontline DLBCL5. EPCOR-RICE - Epcoritamab + R-ICE in Transplant-Eligible R/R DLBCL6. LOTIS-7 Trial - Loncastuximab + Glofitamab in R/R DLBCL7. Additional Studies Mentioned:R-Pola-Glo Frail StudyDLBCL Classification
Embed this episode
NOW PLAYING
Episode 64. Lymphoma Updates from EHA and ICML 2025 with Dr. Adrian Minson
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.